Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 909 matching trials from the live ClinicalTrials.gov search.
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Alimera Sciences
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
3
States / cities
Lexington, Kentucky • Boston, Massachusetts • Cleveland, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Moran AMD Genetic Testing Assessment Study

NCT05265624
Conditions
Age-Related Macular Degeneration, Genetic Testing, Nutritional Biomarkers
Interventions
Early disclosure of genetic testing results, Late disclosure of genetic testing results
Behavioral
Lead sponsor
Paul S. Bernstein
Other
Eligibility
18 Years to 64 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Age - Related Macular Degeneration, Diabetic Retinopathy, Metamorphopsia
Interventions
Paxos Checkup Study Mobile Medical Application
Other
Lead sponsor
Digisight Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
12
States / cities
Phoenix, Arizona • Mountain View, California • Fort Myers, Florida + 9 more
Conditions
Wet Age-related Macular Degeneration
Interventions
KSI-301, Aflibercept, Sham Procedure
Drug · Other
Lead sponsor
Kodiak Sciences Inc
Industry
Eligibility
50 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
65
States / cities
Phoenix, Arizona • Springdale, Arkansas • Bakersfield, California + 60 more
Conditions
Diabetic Macular Edema, Epiretinal Membrane
Interventions
Ozurdex
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Dry Age Related Macular Degeneration
Interventions
Copaxone Injection
Drug
Lead sponsor
The New York Eye & Ear Infirmary
Other
Eligibility
50 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
New York, New York
Conditions
Geographic Atrophy
Interventions
Tinlarebant, Placebo
Drug
Lead sponsor
Belite Bio, Inc
Industry
Eligibility
60 Years to 85 Years
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 19 more
Conditions
Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions
Vitamin A Palmitate
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Age-Related Macular Degeneration, Choroidal Neovascularization, Genetic Counseling
Interventions
Early disclosure, Late disclosure
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Exudative Age-Related Macular Degeneration
Interventions
ranibizumab and dexamethasone, Ranibizumab
Drug
Lead sponsor
Subhransu K. Ray, M.D., Ph.D.
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Walnut Creek, California
Conditions
Neovascular Age-Related Macular Degeneration
Interventions
Lucentis (Ranibizumab)
Drug
Lead sponsor
University of Miami
Other
Eligibility
50 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Miami, Florida
Conditions
Age-related Macular Degeneration
Interventions
small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Conditions
ROSAH
Interventions
DF-003
Drug
Lead sponsor
Shanghai Yao Yuan Biotechnology Ltd. (also known as Drug Farm)
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Bethesda, Maryland • Durham, North Carolina • Salt Lake City, Utah
Conditions
Macular Degeneration, Age Related, Geographic Atrophy
Interventions
Spectralis FAF imaging, Optos imaging, Zeiss Clarus 700 imaging
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
50 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Macular Degeneration
Interventions
Rheopheresis blood filtration
Device
Lead sponsor
OccuLogix
Industry
Eligibility
50 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2005
U.S. locations
7
States / cities
Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 4 more
Conditions
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Interventions
EYE103
Drug
Lead sponsor
EyeBiotech Ltd.
Industry
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
27
States / cities
Phoenix, Arizona • Bakersfield, California • Modesto, California + 23 more
Conditions
Age-related Macular Degeneration (AMD)
Interventions
LMG324, Ranibizumab 0.5 mg, Sham
Biological
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Age Related Macular Degeneration
Interventions
HLX04-O, ranibizumab
Drug
Lead sponsor
Shanghai Henlius Biotech
Industry
Eligibility
50 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
42
States / cities
Gilbert, Arizona • Phoenix, Arizona • Fullerton, California + 34 more
Conditions
Diabetic Macular Edema, Age-related Macular Degeneration
Interventions
MTP-131
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Macular Degeneration
Interventions
Rheopheresis blood filtration
Device
Lead sponsor
OccuLogix
Industry
Eligibility
0 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
8
States / cities
Beverly Hills, California • Coral Gables, Florida • Fort Myers, Florida + 5 more
Conditions
Neovascular Age-related Macular Degeneration (nAMD)
Interventions
RBS-001 Solution for intravitreal injection, Eylea® Solution for intravitreal injection
Drug
Lead sponsor
Rophibio, Inc.
Industry
Eligibility
50 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
7
States / cities
Phoenix, Arizona • Springdale, Arkansas • Erie, Pennsylvania + 3 more
Conditions
Non-exudative Age-related Macular Degeneration
Interventions
Not listed
Lead sponsor
Oregon Health and Science University
Other
Eligibility
60 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Portland, Oregon